Material Agreement, Asset Transaction (Form 8-K)

On September 9, 2025, Traws Pharma, Inc. (the "Company") and Virom, Inc. ("Viriom") entered into an Asset Purchase Agreement (the "Purchase Agreement"), pursuant to which the Company purchased certain assets (the "Purchased Assets") from Viriom in exchange for $2,350,000 in cash (the "Purchase Price"), which was paid in full to Virom on September 9, 2025. The Purchased Assets include certain intellectual property and other assets related to a pyrrolidine antiviral compound (the "Compound"), Viriom's program pipeline related thereto (the "Program") and any pharmaceutical product containing or comprising the Compound (a "Product"), including without limitation certain patents and patent applications; all other intellectual property controlled by Viriom related to the Program, Compound and Product; a third-party license agreement and rights and obligations related thereto; any and all material regulatory or similar filings, applications or associated correspondence related to the development, manufacture of commercialization of the Compound or product; all materials owned or controlled by Viriom related to the Program, Compound or Product; and certain other related assets.

The Purchase Agreement contains customary representations, warranties and covenants. The Purchase Agreement also contains customary indemnification provisions by Viriom in favor of the Company.

The foregoing description of the Purchase Amendment does not purport to be complete and is qualified in its entirety by reference to the full text of the Purchase Amendment, a copy of which is filed as Exhibit 10.1 to this Current Report and is incorporated herein by reference.

Nikolay Savchuk, the Company's Chief Operating Officer, serves as Executive Chairman of Viriom. Additionally, Dr. Savchuk has investment control of Viriom and indirectly holds a significant number of its shares of common stock through a limited liability company of which Dr. Savchuk is the managing member and equity holder. Dr. Robert R. Redfield, M.D., the Company's Chief Medical Officer, serves as a strategic advisor and member of Viriom's board of directors. Each of the Company's Audit Committee and Board of Directors reviewed and approved the Purchase Agreement and related transactions, including the related party nature thereof, and determined that Purchase Agreement and the transactions related thereto were in the best interest of the Company and that the Purchase Price was fair and reasonable.

The information in Item 1.01 of this Current Report on Form 8-K (this "Current Report") regarding the Purchase Agreement and the transactions contemplated thereby is hereby incorporated herein by reference.